IGF-1 LR3
Also known as Long R3 IGF-I, LR3-IGF-1
An 83-amino-acid analogue of insulin-like growth factor I engineered to bind poorly to IGF-binding proteins, which increases its biological potency in vitro and in animals.
Preclinical research
Size
2 options- Catalog no.
- IG01
- Specification
- 0.1mg*10vials
- Per kit
- 10 vials
For laboratory research use only. Not for human or animal consumption. Buyers must be 21 or older.
Overview
IGF-1 LR3 is a recombinant analogue of human IGF-I with an arginine in place of glutamate at position 3 and a 13-amino-acid N-terminal extension. These changes sharply reduce binding to IGF-binding proteins, which normally sequester IGF-I, so more of the analogue stays free to activate the IGF-1 receptor. It was developed in the early 1990s and is widely used in cell culture media. Infusion and injection studies in animals showed greater potency than native IGF-I.
Class: Recombinant IGF-I analogue
Mechanism of action
How the compound acts, as described in the literature.
Activates the type 1 IGF receptor (IGF-1R), a receptor tyrosine kinase that signals through the PI3K–Akt and MAPK pathways.
The Arg3 substitution and N-terminal extension greatly reduce binding to IGF-binding proteins, increasing the free, active fraction.
IGF-1R signaling promotes cell growth, protein synthesis and glucose uptake in target tissues.
Lower binding-protein affinity extends effective activity compared with native IGF-I in animal models.
Published research
Selected studies, each linked to its PubMed record. Summaries describe what the studies reported.
1992
In vitro study
PMID 1378742Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency.
Francis GL, et al. · J Mol Endocrinol
Showed that IGF-I analogues with reduced IGF-binding protein binding, including the Long R3 form, had markedly enhanced biological potency in vitro.
1996
Rodent study
PMID 8708565Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection.
Tomas FM, et al. · J Endocrinol
In rats, IGF-I analogues with weak binding-protein affinity were more potent than native IGF-I, both when infused and when injected.
Evidence & safety
What the research does not show, and the adverse events and regulatory status it reports.
All published evidence is from cell culture and animal studies; there are no human trials. IGF-1 receptor signaling lowers blood glucose, and hypoglycemia is a recognized effect of IGF-I class compounds. Long-term effects on cell proliferation are not characterized.
Specifications
All sizes, exactly as catalogued.
| Catalog no. | Product | Specification | Vials per kit |
|---|---|---|---|
| IG01 | IGF-1 LR3 | 0.1mg*10vials | 10 |
| IG1 | IGF-1 LR3 | 1mg*10vials | 10 |
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease. Research summaries are provided for educational purposes and do not describe this product’s use.